The Intercept Pharmaceuticals’ (ICPT) “Outperform” Rating Reiterated at Wedbush

The Intercept Pharmaceuticals’ (ICPT) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) in a research note issued to investors on Friday. Wedbush currently has a $239.00 price target on the biopharmaceutical company’s stock.

ICPT has been the topic of a number of other reports. Robert W. Baird reiterated an outperform rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 15th. Credit Suisse Group AG reissued a buy rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, August 5th. Vetr cut Intercept Pharmaceuticals from a sell rating to a strong sell rating and set a $81.50 price objective on the stock. in a research note on Monday, August 8th. Oppenheimer Holdings Inc. reduced their price objective on Intercept Pharmaceuticals from $265.00 to $250.00 and set an outperform rating on the stock in a research note on Friday, August 5th. Finally, Cantor Fitzgerald reissued a sell rating and set a $60.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, August 8th. Five research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. Intercept Pharmaceuticals presently has a consensus rating of Hold and an average target price of $177.67.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 151.84 on Friday. The stock has a 50 day moving average price of $156.85 and a 200-day moving average price of $151.25. The stock’s market cap is $3.75 billion. Intercept Pharmaceuticals has a 1-year low of $89.76 and a 1-year high of $217.99.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to the consensus estimate of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The firm’s revenue for the quarter was up 1140.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.99) earnings per share. On average, equities analysts expect that Intercept Pharmaceuticals will post ($16.31) EPS for the current year.

In other news, CMO David Shapiro sold 3,545 shares of the stock in a transaction on Monday, September 26th. The stock was sold at an average price of $165.08, for a total transaction of $585,208.60. Following the completion of the sale, the chief marketing officer now owns 45,732 shares in the company, valued at approximately $7,549,438.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Lisa Bright sold 155 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $163.20, for a total value of $25,296.00. Following the sale, the insider now owns 18,305 shares of the company’s stock, valued at approximately $2,987,376. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Mizuho Securities USA Inc. acquired a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $984,000. Bellevue Group AG acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter valued at approximately $1,734,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter valued at approximately $1,675,000. Legal & General Group Plc raised its stake in shares of Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 156 shares in the last quarter. Finally, National Planning Corp raised its stake in shares of Intercept Pharmaceuticals by 92.7% in the first quarter. National Planning Corp now owns 50,510 shares of the biopharmaceutical company’s stock valued at $6,735,000 after buying an additional 24,305 shares in the last quarter. Hedge funds and other institutional investors own 81.86% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment